In light of recently evolving regulatory guidance on intake limits for nitrosamines in medications, enrollment of new patients in ribociclib early breast cancer (eBC) studies has been paused by Novartis in alignment with health authorities

[pragnesh]

Novartis implements manufacturing adjustments for ribociclib to ensure...